pages 241 and 249.
Tumor-specific T cells can be detected in the blood and the tumors of many melanoma patients, and yet these cells are unable to kill the tumor. What causes the impotence of these T cells is a mystery. Equally mysterious is why vaccination against tumor-specific antigens sometimes causes regression without expanding large numbers of vaccine-specific killer T cells.Pierre Coulie's group studied the specificity of antitumor T cell responses in patients vaccinated with a tumor antigen called MAGE-3. In one patient whose tumors regressed after vaccination, the authors found that T cells specific for nonvaccine tumor antigens became detectable or expanded from their prevaccine frequencies. Vaccine-specific T cells became detectable but remained at low frequency. Thus, reinvigoration of existing tumor-specific T cells and activation of new T cells after vaccination does not require large numbers of vaccine-specific T cells.
Although the mechanism underlying this phenomenon remains unknown, Coulie thinks that the few T cells stimulated by the vaccine may change the local environment of the tumor such that existing T cells can be reactivated and new T cells can be recruited.